Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;97(6):730-739.
doi: 10.1111/cen.14793. Epub 2022 Jul 4.

Ambulatory fludrocortisone suppression test in the diagnosis of primary aldosteronism: Safety, accuracy and cost-effectiveness

Ana Carasel  1   2 , Jan Calissendorff  1   2 , Kamila Avander  3 , Ivan Shabo  2   4 , Cristina Volpe  1   2 , Henrik Falhammar  1   2
Affiliations

Ambulatory fludrocortisone suppression test in the diagnosis of primary aldosteronism: Safety, accuracy and cost-effectiveness

Ana Carasel et al. Clin Endocrinol (Oxf). 2022 Dec.

Abstract

Objective: The aims of this study were to explore if the ambulatory fludrocortisone suppression test (FST) was safe, accurate and cost-effective.

Context: The diagnosis of primary aldosteronism (PA) remains time-consuming and complex. The FST is used to confirm PA, but it is an in-patient test due to potentially serious complications such as hypokalemia. In Stockholm, FST has been performed since 2005 as an ambulatory procedure.

Design: This is a retrospective study including all patients investigated with FST in four hospitals in Stockholm, Sweden, during 2005-2019.

Patients/measurements: In total, 156 cases of ambulatory FST (FSTamb) and 15 cases of in-patient FST (FSTin) were included. FSTamb and FSTin were compared regarding health costs, clinical characteristics and laboratory results.

Results: No difference was found in the outcomes of FSTamb and FSTin. No severe complications were reported in FSTamb patients. No difference was found in the median value for plasma potassium on Day 5 between the two groups. Only three patients (1.9%) in the FSTamb had to repeat the test due to incomplete intake of medications. FSTamb and FSTin were equally accurate. The cost of performing FSTamb was at least 50% lower compared with FSTin ($2400 vs. $5200 per patient). The time needed for FSTamb was 60 min of physician's time and 150 min of nurse's time which were lower than the 5 days in FSTin.

Conclusions: Ambulatory FST is safe and accurate and can be performed with significantly less healthcare costs compared to FSTin.

Keywords: ambulatory; fludrocortisone suppression test; primary aldosteronism.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(A) Plasma potassium variation during fludrocortisone suppression test (FST) in‐patient FST (FST)in and ambulatory FST (FSTamb). (B) Plasma potassium variation during FSTamb in the four centres in Stockholm. (C) Plasma potassium variation FSTamb and FSTin in Stockholm when excluding the centre without daily control of plasma potassium.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Galati SJ. Primary aldosteronism: challenges in diagnosis and management. Endocrinol Metab Clin North Am. 2015;44(2):355‐369. - PubMed
    1. Gkaniatsa E, Ekerstad E, Gavric M, et al. Increasing incidence of primary aldosteronism in Western Sweden during 3 decades—yet an underdiagnosed disorder. J Clin Endocrinol Metab. 2021;106(9):e3603‐e3610. - PMC - PubMed
    1. Xu Z, Yang J, Hu J, et al. Primary aldosteronism in patients in China with recently detected hypertension. J Am Coll Cardiol. 2020;75(16):1913‐1922. - PubMed
    1. Monticone S, Burrello J, Tizzani D, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol. 2017;69(14):1811‐1820. - PubMed
    1. Libianto R, Russell GM, Stowasser M, et al. Detecting primary aldosteronism in Australian primary care: a prospective study. Med J Aust. 2022;216:408‐412. - PubMed